Skip to main content

Table 5 The 10 Most Frequent AEs (Safety Population)

From: Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis

 

Lumiracoxib 100 mg o.d. (n = 755)

Lumiracoxib 100 mg b.i.d. (n = 1,519)

Celecoxib 200 mg o.d. (n = 758)

Headache

82 (10.9)

174 (11.5)

82 (10.8)

Nasopharyngitis

80 (10.6)

141 (9.3)

75 (9.9)

Back pain

46 (6.1)

87 (5.7)

52 (6.9)

Arthralgia

53 (7.0)

82 (5.4)

41 (5.4)

Abdominal pain upper

42 (5.6)

88 (5.8)

35 (4.6)

Upper respiratory tract infection

36 (4.8)

86 (5.7)

43 (5.7)

Dyspepsia

38 (5.0)

85 (5.6)

39 (5.1)

Urinary tract infection

38 (5.0)

75 (4.9)

24 (3.2)

Sinusitis

21 (2.8)

58 (3.8)

34 (4.5)

Influenza

30 (4.0)

53 (3.5)

28 (3.7)

  1. o.d. = once daily; b.i.d. = twice daily.